RASAL1 inhibits HepG2 cell growth via HIF-2α mediated gluconeogenesis

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• RAS protein activator like 1 (RASAL1) is a known tumor suppressor.
• RASAL1 belongs to the RAS GTPase-activating protein (GAP) family.
• Decreased RASAL1 levels correlate with advanced pathological stage and larger tumor size in human liver cancer.

Purpose of the Study:

• To investigate the inhibitory role of RASAL1 in liver cancer.
• To elucidate the molecular mechanisms underlying RASAL1's function in liver cancer.
• To evaluate RASAL1 as a potential therapeutic target for liver cancer.

Main Methods:

• Assessing the effect of exogenous RASAL1 expression on HepG2 cell proliferation and invasion.
• Investigating the impact of RASAL1 overexpression on HIF-2α transcription activity and gluconeogenesis.
• Evaluating the effect of RASAL1 on xenograft tumor growth in nude mice.
• Analyzing the expression of hypoxia-inducible factor (HIF)-2α and gluconeogenesis enzymes.

Main Results:

• Exogenous RASAL1 expression inhibited HepG2 cell proliferation and invasion.
• RASAL1 overexpression downregulated HIF-2α transcription activity and HIF-2α-mediated gluconeogenesis via ERK1/2 activation.
• RASAL1 reduced xenograft tumor size by inhibiting HIF-2α and gluconeogenesis enzyme expression.

Conclusions:

• The RASAL1/HIF-2α axis plays a critical role in the growth of HepG2 liver cancer cells.
• RASAL1 acts as a tumor suppressor in liver cancer by inhibiting cell proliferation, invasion, and gluconeogenesis.
• The RASAL1/HIF-2α signaling cascade represents a potential novel therapeutic target for liver cancer treatment.